Dutta D, Kamrul-Hasan AB, Nagendra L, Bhattacharya S
The Takeaway Semaglutide and other GLP-1 drugs are associated with a wide variety of adverse events, most commonly gastrointestinal distress
These mixed responses cannot be generalized, but the fact that a subset experience real improvement makes this an important signal to investigate
A personalized program is necessary because your starting point matters
Noteworthy, after pairwise comparison of SEMA/HFD at T2 (Fig
Second, the gap between tirzepatide and retatrutide (approximately 6 percentage points) is smaller than the gap between semaglutide and tirzepatide (approximately 7-8 percentage points), which means the incremental benefit of adding glucagon agonism is real but not proportionally larger than the benefit of adding GIP